Skip to main content

Articles

Page 1 of 8

  1. Metabolic reprogramming, fundamentally pivotal in carcinogenesis and progression of cancer, is considered as a promising therapeutic target against tumors. In chronic lymphocytic leukemia (CLL) cells, metaboli...

    Authors: Yu Nie, Xiaoya Yun, Ya Zhang and Xin Wang
    Citation: Experimental Hematology & Oncology 2022 11:39
  2. T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell thera...

    Authors: Yikai Zhang, Zhipeng Liu, Wei Wei and Yangqiu Li
    Citation: Experimental Hematology & Oncology 2022 11:38
  3. The application of hematopoietic stem cells (HSCs) has been restricted due to limited cell sources and conventional methods for generating these cells by cell expansion and pluripotent stem cell differentiatio...

    Authors: Liaoliao Dong, Chuijin Wei, Shumin Xiong, Ping Yu, Ren Zhou and Lin Cheng
    Citation: Experimental Hematology & Oncology 2022 11:37
  4. Tyrosine kinase inhibitors have achieved quite spectacular advances in the treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance that related to the T315I mutation, remain ma...

    Authors: Zhuanyun Du, Zhenglan Huang, Xi Chen, Guoyun Jiang, Yuhang Peng, Wenli Feng and Ningshu Huang
    Citation: Experimental Hematology & Oncology 2022 11:36
  5. Transfer RNAs (tRNAs) promote protein translation by binding to the corresponding amino acids and transporting them to the ribosome, which is essential in protein translation. tRNA-derived small RNAs (tsRNAs) ...

    Authors: Xinliang Gu, Yu Zhang, Xinyue Qin, Shuo Ma, Yuejiao Huang and Shaoqing Ju
    Citation: Experimental Hematology & Oncology 2022 11:35
  6. Chronic graft-versus-host disease (cGVHD) remains a major complication during the late phase of allogeneic hematopoietic stem cell transplantation (allo-HSCT). IL-39, a newly described pro-inflammatory cytokin...

    Authors: Kangkang Lv, Bo Hu, Mingzhu Xu, Li Wan, Ziqi Jin, Mimi Xu, Yuanyuan Du, Kunpeng Ma, Quansheng Lv, Yang Xu, Lei Lei, Huanle Gong, Haiyan Liu, Depei Wu and Yuejun Liu
    Citation: Experimental Hematology & Oncology 2022 11:34
  7. With the widespread clinical application of tyrosine kinase inhibitors (TKIs), an increasing number of chronic myeloid leukaemia (CML) patients have developed resistance or intolerance to TKIs. BCR/ABL is the ...

    Authors: Dachuan Zeng, Miao Gao, Renren Zheng, Run Qin, Wei He, Suotian Liu, Wei Wei and Zhenglan Huang
    Citation: Experimental Hematology & Oncology 2022 11:33
  8. Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Cauca...

    Authors: Yanbo Nie, Liang Shao, Hong Zhang, Colin K. He, Hongyu Li, Junyan Zou, Long Chen, Huaiyue Ji, Hao Tan, Yani Lin and Kun Ru
    Citation: Experimental Hematology & Oncology 2022 11:32
  9. As the most common and abundant RNA modification in eukaryotic cells, N6-methyladenosine (m6A) modification plays an important role in different stages of tumor. m6A can participate in the regulation of tumor ...

    Authors: Ze Zhang, Furong Liu, Wei Chen, Zhibin Liao, Wanguang Zhang, Bixiang Zhang, Huifang Liang, Liang Chu and Zhanguo Zhang
    Citation: Experimental Hematology & Oncology 2022 11:30
  10. Leukemia stem cells (LSCs) are responsible for the initiation and perpetuation of acute myeloid leukemia (AML), and also represent leukemia relapse reservoirs with limited therapeutic approaches. Thus, additio...

    Authors: Haijun Zhao, Yuelong Jiang, Fusheng Lin, Mengya Zhong, Jinshui Tan, Yong Zhou, Long Liu, Guowei Li, Manman Deng and Bing Xu
    Citation: Experimental Hematology & Oncology 2022 11:29
  11. Myelodysplastic syndromes (MDS) are generally considered as a group of clonal diseases derived from hematopoietic stem cells, but a number of studies have suggested that they are derived from myeloid progenito...

    Authors: Bingqing Luo, Fang Dong, Tiejun Qin, Qingyun Zhang, Haitao Bai, Jinhong Wang, Yujiao Jia, Shihui Ma, Erlie Jiang, Tao Cheng, Zhijian Xiao and Hideo Ema
    Citation: Experimental Hematology & Oncology 2022 11:28
  12. Engineered T cells have been shown to be highly effective in cancer immunotherapy, although T cell exhaustion presents a challenge for their long-term function. Additional T-cell sources must be exploited to b...

    Authors: Rongqun Guo, Wei Li, Yadan Li, Yingmei Li, Zhongxing Jiang and Yongping Song
    Citation: Experimental Hematology & Oncology 2022 11:27
  13. CD47/SIRPα axis is recognized as an innate immune checkpoint and emerging clinical data validate the interest of interrupting this pathway in cancer, particularly in hematological malignancies. In preclinical ...

    Authors: Xavier Chauchet, Laura Cons, Laurence Chatel, Bruno Daubeuf, Gérard Didelot, Valéry Moine, Didier Chollet, Pauline Malinge, Guillemette Pontini, Krzysztof Masternak, Walter Ferlin, Vanessa Buatois and Limin Shang
    Citation: Experimental Hematology & Oncology 2022 11:26
  14. Acute graft-versus-host disease (aGVHD) remains the major cause of early mortality after haploidentical related donor (HID) hematopoietic stem cell transplantation (HSCT). We aimed to establish a comprehensive...

    Authors: Meng-Zhu Shen, Shen-Da Hong, Rui Lou, Rui-Ze Chen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang and Xiao-Dong Mo
    Citation: Experimental Hematology & Oncology 2022 11:25
  15. Dysregulation of MDM2, a p53 negative regulator, frequently occurs in acute myeloid leukemia (AML) and is associated with unfavorable prognoses, rendering the p53-MDM2 axis an attractive target for the develop...

    Authors: Qinwei Chen, Suqi Deng, Manman Deng, Yuanfei Shi, Mengya Zhong, Lihong Ding, Yuelong Jiang, Yong Zhou, Bing Z. Carter and Bing Xu
    Citation: Experimental Hematology & Oncology 2022 11:23
  16. Very few reports elucidate the prognosis of patients with TP53 aberrations using both measurable residual disease (MRD) and the status of having undergone allogeneic hematopoietic stem cell transplantation (allo-...

    Authors: Qiuyun Fang, Xiaoyuan Gong, Kaiqi Liu, Yujiao Jia, Yang Song, Guangji Zhang, Yan Li, Qishan Hao, Yueshen Ma, Shuning Wei, Bingcheng Liu, Ying Wang, Hui Wei, Jianxiang Wang and Yingchang Mi
    Citation: Experimental Hematology & Oncology 2022 11:22
  17. YT521-B homology domain family member 2 (YTHDF2) is an N6-methyladenosine (m6A)-binding protein that was originally found to regulate the stability of mRNA. Growing evidence has shown that YTHDF2 can participate ...

    Authors: Xiaomin Chen, Xiangxiang Zhou and Xin Wang
    Citation: Experimental Hematology & Oncology 2022 11:21
  18. Physical activity is known to have anti-cancer effects, including immunomodulatory actions. This study investigated the hypothesis that physical activity synergizes with combined lenvatinib plus anti-PD-1 ther...

    Authors: Xue-Feng Liu, Xiao-Dong Zhu, Long-Hai Feng, Xiao-Long Li, Bin Xu, Kang-Shuai Li, Nan Xiao, Ming Lei, Hui-Chuan Sun and Zhao-You Tang
    Citation: Experimental Hematology & Oncology 2022 11:20
  19. The glycoprotein (GP) Ib-IX complex is a platelet receptor that mediates the initial interaction with subendothelial von Willebrand factor (VWF) causing platelet arrest at sites of vascular injury even under c...

    Authors: Gerd Bendas and Martin Schlesinger
    Citation: Experimental Hematology & Oncology 2022 11:19
  20. IRE1 is an unfolded protein response (UPR) sensor with kinase and endonuclease activity. It plays a central role in the endoplasmic reticulum (ER) stress response through unconventional splicing of XBP1 mRNA a...

    Authors: Dalia Quwaider, Luis A. Corchete, Marta Martín-Izquierdo, Jesús M. Hernández-Sánchez, Elizabeta A. Rojas, Ignacio J. Cardona-Benavides, Ramón García-Sanz, Ana B. Herrero and Norma C. Gutiérrez
    Citation: Experimental Hematology & Oncology 2022 11:18
  21. There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons ...

    Authors: Guillaume Cartron, Christopher P. Fox, Fei Fei Liu, Ana Kostic, Jens Hasskarl, Daniel Li, Ashley Bonner, Yixie Zhang, David G. Maloney and John Kuruvilla
    Citation: Experimental Hematology & Oncology 2022 11:17
  22. An elevated platelet count has been associated with an increased incidence of cancer and poor survival for many cancer types. In this study, platelet levels were captured among cancer patients in the 2 years p...

    Authors: Vasily Giannakeas
    Citation: Experimental Hematology & Oncology 2022 11:16
  23. CD19 chimeric antigen receptor (CAR) therapy has achieved impressive success in relapsed or refractory (R/R) B-cell malignancies, but relapse due to antigen escape is increasingly appearing reported. As the ex...

    Authors: Yu Zhang, Saisai Li, Ying Wang, Yang Lu, Yingxi Xu, Qing Rao, Huijun Wang, Haiyan Xing, Zheng Tian, Kejing Tang, Lulu Lv, Min Wang and Jianxiang Wang
    Citation: Experimental Hematology & Oncology 2022 11:15
  24. N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the ...

    Authors: Yu-qing Guo, Qiang Wang, Jun-guo Wang, Ya-jun Gu, Pan-pan Song, Shou-yu Wang, Xiao-yun Qian and Xia Gao
    Citation: Experimental Hematology & Oncology 2022 11:14
  25. The differential signaling and outcome of patients with p190 or p210 transcripts of BCR-ABL1 have been systematically investigated in chronic myeloid leukemia rather than in Philadelphia chromosome-positive ac...

    Authors: Ting Shi, Mixue Xie, Li Chen, Wei Yuan, Yungui Wang, Xin Huang, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Wenjuan Yu, Hongyan Tong, Xiujin Ye, Jinyan Huang, Jie Jin and Honghu Zhu
    Citation: Experimental Hematology & Oncology 2022 11:13
  26. Previous studies have shown increased aberrant expression of immune checkpoint (IC) proteins, such as programmed cell death receptor-1 (PD-1) and T cell immunoglobulin mucin-domain-containing-3 (Tim-3) on T ce...

    Authors: Yujie Zhao, Pengjun Liao, Shuxin Huang, Tairan Deng, Jiaxiong Tan, Youxue Huang, Huien Zhan, Yangqiu Li, Shaohua Chen and Liye Zhong
    Citation: Experimental Hematology & Oncology 2022 11:12
  27. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associat...

    Authors: Xingcheng Yang, Ling Ma, Xiaoying Zhang, Liang Huang and Jia Wei
    Citation: Experimental Hematology & Oncology 2022 11:11
  28. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. However, there is no data on the safety and efficacy of CAR T-cell therapy in patient...

    Authors: Bradley D. Hunter, Daanish Hoda, Andy Nguyen, Launce Gouw, Bryan Huber, Ryan R. Jensen, Justine Preedit, Andrew Evens, Esther Huang, Jiyeon Park and Dennis L. Cooper
    Citation: Experimental Hematology & Oncology 2022 11:10
  29. This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (...

    Authors: Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura, Hisashi Tsurumi and Masahito Shimizu
    Citation: Experimental Hematology & Oncology 2022 11:9
  30. Follow-up of low-risk monoclonal gammopathy of undetermined significance (MGUS) is debated as multiple myeloma (MM) progression risk is low. Worse MM outcome was reported for patients followed for low-risk MGU...

    Authors: Widad Tahiru, Antonio Izarra Santamaria, Johan Hultdin, Wendy Yi-Ying Wu and Florentin Späth
    Citation: Experimental Hematology & Oncology 2022 11:8
  31. VEXAS (vacuoles, E1 enzyme, X-linked, auto-inflammatory, somatic) syndrome is an inflammatory disorder with hematological and systemic features. A recent study demonstrated that the dermal infiltrate in neutro...

    Authors: Valentin Lacombe, Annaelle Beucher, Geoffrey Urbanski, Yannick Le Corre, Laurane Cottin, Anne Croué and Anne Bouvier
    Citation: Experimental Hematology & Oncology 2022 11:6
  32. Multiple myeloma (MM) remains an incurable malignancy, despite the advent of therapies such as proteosome inhibitors (PIs) that disrupt protein homeostasis and induce ER stress. We have pursued inhibition of g...

    Authors: Staci L. Haney, Michelle L. Varney, Jacob T. Williams, Lynette M. Smith, Geoffrey Talmon and Sarah A. Holstein
    Citation: Experimental Hematology & Oncology 2022 11:5
  33. Dendritic cell (DC) vaccines induce specific immune responses that can selectively eliminate target cells. In recent years, many studies have been conducted to explore DC vaccination in the treatment of hemato...

    Authors: Jifeng Yu, Hao Sun, Weijie Cao, Yongping Song and Zhongxing Jiang
    Citation: Experimental Hematology & Oncology 2022 11:3
  34. Tanshinone II A is an effective component extracted from Salvia miltiorrhiza and the roles of Tanshinone IIA in regulating the stemness of tumor cells remain unclear. This work aims to explore the roles and un...

    Authors: Xiaoman Li, Qi Jia, Yinyin Zhou, Xuan Jiang, Li Song, Yuanyuan Wu, Aiyun Wang, Wenxing Chen, Shijun Wang and Yin Lu
    Citation: Experimental Hematology & Oncology 2022 11:2
  35. Paroxysmal nocturnal hemoglobinuria is a clonal disease caused by PIG-A mutation of hematopoietic stem cells. At present, there is no suitable PNH animal model for basic research, therefore, it is urgent to estab...

    Authors: Yingying Chen, Hui Liu, Lijie Zeng, Liyan Li, Dan Lu, Zhaoyun Liu and Rong Fu
    Citation: Experimental Hematology & Oncology 2022 11:1
  36. Macrophages are heterogeneous cells that present as different functional phenotypes due to their plasticity. They can be classified into two categories, namely M1- and M2-like macrophages, which are involved i...

    Authors: Shuangli Zhu, Ming Yi, Yuze Wu, Bing Dong and Kongming Wu
    Citation: Experimental Hematology & Oncology 2021 10:60

    The Correction to this article has been published in Experimental Hematology & Oncology 2022 11:4

  37. Selinexor, an oral selective inhibitor of nuclear export (SINE), was demonstrated to hinder the DNA damage repair (DDR) system by reducing DDR proteins while enhancing the killing of cancer cells by DDR-based ...

    Authors: Kyaw Z. Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Siqing Fu, Vivek Subbiah, David S. Hong, Timothy A. Yap, Jatin Shah, Denái R. Milton, Lacey McQuinn, Jing Gong, Yanyan Tran, Brett W. Carter, Rivka Colen…
    Citation: Experimental Hematology & Oncology 2021 10:59
  38. Interferon regulatory factor 4 (IRF4) is involved in the pathogenesis of various hematologic malignancies. Its expression has been related to the negative regulation of myeloid-derived suppressor cells (MDSCs) an...

    Authors: Cosimo Cumbo, Francesco Tarantini, Luisa Anelli, Antonella Zagaria, Immacolata Redavid, Crescenzio Francesco Minervini, Nicoletta Coccaro, Giuseppina Tota, Alessandra Ricco, Elisa Parciante, Maria Rosa Conserva, Giorgina Specchia, Pellegrino Musto and Francesco Albano
    Citation: Experimental Hematology & Oncology 2021 10:58
  39. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a life-threatening syndrome that occurs in adult and pediatric patients after hematopoietic stem cell transplantation...

    Authors: Eleni Gavriilaki, Vincent T. Ho, Wilhelm Schwaeble, Thomas Dudler, Mohamed Daha, Teizo Fujita and Sonata Jodele
    Citation: Experimental Hematology & Oncology 2021 10:57
  40. Cancer immunotherapy has made remarkable progress in the past decade. Bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-target cancer immunotherapy, which o...

    Authors: Yuze Wu, Ming Yi, Shuangli Zhu, Haiyong Wang and Kongming Wu
    Citation: Experimental Hematology & Oncology 2021 10:56
  41. Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a mul...

    Authors: Emma Rabinovich, Kith Pradhan, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Ioannis Mantzaris, Noah Kornblum, Aditi Shastri, Kira Gritsman, Mendel Goldfinger, Amit Verma and Ira Braunschweig
    Citation: Experimental Hematology & Oncology 2021 10:55
  42. Hepatocellular carcinoma (HCC) is a common malignancy in human. CD44 is a transmembrane glycoprotein which is frequently overexpressed in cancer of various origins. The function and mechanism of CD44 in HCC re...

    Authors: Jun Zhang, Xilin He, Yajie Wan, Honghong Zhang, Tao Tang, Meng Zhang, Shiyi Yu, Weiyong Zhao and Liming Chen
    Citation: Experimental Hematology & Oncology 2021 10:54
  43. Human gastrointestinal malignancies are highly heterogeneous cancers. Clinically, heterogeneity largely contributes to tumor progression and resistance to therapy. Heterogeneity within gastrointestinal cancers...

    Authors: Mei-Mei Li, Jun Yuan, Xin-Yuan Guan, Ning-Fang Ma and Ming Liu
    Citation: Experimental Hematology & Oncology 2021 10:53
  44. MET amplification plays an important role in the development of non-small-cell lung cancer (NSCLC) either de novo or in resistance to epidermal growth factor receptor tyrosine–kinase inhibitor (EGFR-TKI) settings...

    Authors: Lun-Xi Peng, Guang-Ling Jie, An-Na Li, Si-Yang Liu, Hao Sun, Mei-Mei Zheng, Jia-Ying Zhou, Jia-Tao Zhang, Xu-Chao Zhang, Qing Zhou, Wen-Zhao Zhong, Jin-Ji Yang, Hai-Yan Tu, Jian Su, Hong-Hong Yan and Yi-Long Wu
    Citation: Experimental Hematology & Oncology 2021 10:52
  45. Chromosomal translocations are the main etiological factor of hematologic malignancies. These translocations are generally the consequence of aberrant DNA double-strand break (DSB) repair. DSBs arise either ex...

    Authors: Mohsen Valikhani, Elahe Rahimian, Seyed Esmaeil Ahmadi, Rouzbeh Chegeni and Majid Safa
    Citation: Experimental Hematology & Oncology 2021 10:51
  46. The in vitro erythrocyte differentiation model remains a strong, clinically relevant tool to model erythroid development in normal and disease related hematopoiesis. This model also has application to developi...

    Authors: Matthew Cannon, Hannah Phillips, Sidney Smith, Shaneice Mitchell, Kristina Landes, Payal Desai, John Byrd and Rosa Lapalombella
    Citation: Experimental Hematology & Oncology 2021 10:50

Annual Journal Metrics